<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" dtd-version="1.0" article-type="reference-list">
<front>
<article-meta>
<custom-meta-group>
<custom-meta><meta-name>TotalReferences</meta-name><meta-value>77</meta-value></custom-meta>
<custom-meta><meta-name>ReferencesParsed</meta-name><meta-value>33</meta-value></custom-meta>
<custom-meta><meta-name>ReferencesBillable</meta-name><meta-value>41</meta-value></custom-meta>
<custom-meta><meta-name>LinkServices</meta-name><meta-value>pubmed-crossref</meta-value></custom-meta>
<custom-meta><meta-name>ReferencesLinked</meta-name><meta-value>39</meta-value></custom-meta>
<custom-meta><meta-name>ReferencesLinkedDOI</meta-name><meta-value>38</meta-value></custom-meta>
<custom-meta><meta-name>ReferencesLinkedPMID</meta-name><meta-value>31</meta-value></custom-meta>
<custom-meta><meta-name>JournalReferences</meta-name><meta-value>33</meta-value></custom-meta>
<custom-meta><meta-name>BookReferences</meta-name><meta-value>0</meta-value></custom-meta>
<custom-meta><meta-name>BookChapterReferences</meta-name><meta-value>0</meta-value></custom-meta>
<custom-meta><meta-name>ConferenceReferences</meta-name><meta-value>0</meta-value></custom-meta>
<custom-meta><meta-name>ElectronicReferences</meta-name><meta-value>5</meta-value></custom-meta>
<custom-meta><meta-name>DissertationReferences</meta-name><meta-value>0</meta-value></custom-meta>
<custom-meta><meta-name>LegalReferences</meta-name><meta-value>0</meta-value></custom-meta>
<custom-meta><meta-name>StandardReferences</meta-name><meta-value>0</meta-value></custom-meta>
<custom-meta><meta-name>OtherReferences</meta-name><meta-value>0</meta-value></custom-meta>
<custom-meta><meta-name>UnknownReferences</meta-name><meta-value>39</meta-value></custom-meta>
<custom-meta><meta-name>ReferencesSemiParsed</meta-name><meta-value>0</meta-value></custom-meta>
<custom-meta><meta-name>ReferencesBookUnparsed</meta-name><meta-value>0</meta-value></custom-meta>
<custom-meta><meta-name>EditorialStyle</meta-name><meta-value>ICMJE-WHO</meta-value></custom-meta>
</custom-meta-group>
</article-meta>
</front>
<back>
<ref-list>
<ref id="b1"><label>1.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Jazbec</surname> <given-names>J</given-names></string-name>, <string-name><surname>Rajic</surname> <given-names>V</given-names></string-name>, <string-name><surname>Karas-Kuzelicki</surname> <given-names>N</given-names></string-name></person-group>. <article-title>Leukemias of Childhood</article-title>. <source>Zdr Vestn-Slov Med J.</source> <year>2008</year> <month>Apr</month>;<volume>77</volume>:<fpage>I25</fpage>–<lpage>30</lpage>.</mixed-citation></ref>
<ref id="b2"><label>2.        </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Pui</surname> <given-names>C-H</given-names></string-name>, <string-name><surname>Evans</surname> <given-names>WE. A</given-names></string-name></person-group> 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia. Semin Hematol. 1. julij <year>2013</year>.;50(3):185–96.</mixed-citation></ref>
<ref id="b3"><label>3.        </label><mixed-citation publication-type="unknown" specific-use="linked"><person-group person-group-type="author"><string-name><surname>Oldenhuis</surname> <given-names>CN</given-names></string-name>, <string-name><surname>Oosting</surname> <given-names>SF</given-names></string-name>, <string-name><surname>Gietema</surname> <given-names>JA</given-names></string-name>, <string-name><surname>de Vries</surname> <given-names>EG</given-names></string-name></person-group>. <article-title>Prognostic versus predictive value of biomarkers in oncology.</article-title> Eur J Cancer. maj <year>2008</year>.;44(7):946–53. <pub-id pub-id-type="doi">10.1016/j.ejca.2008.03.006</pub-id></mixed-citation></ref>
<ref id="b4"><label>4.        </label><mixed-citation publication-type="unknown" specific-use="linked"><person-group person-group-type="author"><string-name><surname>Friedmann</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Weinstein</surname> <given-names>HJ</given-names></string-name></person-group>. <article-title>The Role of Prognostic Features in the Treatment of Childhood Acute Lymphoblastic Leukemia.</article-title> The Oncologist. 8. januar <year>2000</year>.;5(4):321–8. <pub-id pub-id-type="doi">10.1634/theoncologist.5-4-321</pub-id></mixed-citation></ref>
<ref id="b5"><label>5.        </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Burger</surname> <given-names>B</given-names></string-name>, <string-name><surname>Zimmermann</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mann</surname> <given-names>G</given-names></string-name>, <string-name><surname>Kuhl</surname> <given-names>J</given-names></string-name>, <string-name><surname>Loning</surname> <given-names>L</given-names></string-name>, <string-name><surname>Riehm</surname> <given-names>H</given-names></string-name></person-group>, in sod. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol. 15. januar <year>2003</year>.;21(2):184–8.</mixed-citation></ref>
<ref id="b6"><label>6.        </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Kaspers</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Smets</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Pieters</surname> <given-names>R</given-names></string-name>, <string-name><surname>Van Zantwijk</surname> <given-names>CH</given-names></string-name>, <string-name><surname>Van Wering</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Veerman</surname> <given-names>AJ</given-names></string-name></person-group>. <article-title>Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study.</article-title> Blood. 1. februar <year>1995</year>.;85(3):751–6.</mixed-citation></ref>
<ref id="b7"><label>7.        </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Loh</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Goldwasser</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Silverman</surname> <given-names>LB</given-names></string-name>, <string-name><surname>Poon</surname> <given-names>WM</given-names></string-name>, <string-name><surname>Vattikuti</surname> <given-names>S</given-names></string-name>, <string-name><surname>Cardoso</surname> <given-names>A</given-names></string-name></person-group>, in sod. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood. 1. junij <year>2006</year>.;107(11):4508–13.</mixed-citation></ref>
<ref id="b8"><label>8.        </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Schrappe</surname> <given-names>M</given-names></string-name>, <string-name><surname>Arico</surname> <given-names>M</given-names></string-name>, <string-name><surname>Harbott</surname> <given-names>J</given-names></string-name>, <string-name><surname>Biondi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Zimmermann</surname> <given-names>M</given-names></string-name>, <string-name><surname>Conter</surname> <given-names>V</given-names></string-name></person-group>, in sod. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood. 15. oktober <year>1998</year>.;92(8):2730–41.</mixed-citation></ref>
<ref id="b9"><label>9.        </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Johansson</surname> <given-names>B</given-names></string-name>, <string-name><surname>Moorman</surname> <given-names>AV</given-names></string-name>, <string-name><surname>Haas</surname> <given-names>OA</given-names></string-name>, <string-name><surname>Watmore</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Cheung</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Swanton</surname> <given-names>S</given-names></string-name></person-group>, in sod. Hematologic malignancies with t(4;11)(q21;q23)--a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop participants. Leukemia. maj <year>1998</year>.;12(5):779–87.</mixed-citation></ref>
<ref id="b10"><label>10.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Crist</surname> <given-names>WM</given-names></string-name>, <string-name><surname>Carroll</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Shuster</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Behm</surname> <given-names>FG</given-names></string-name>, <string-name><surname>Whitehead</surname> <given-names>M</given-names></string-name>, <string-name><surname>Vietti</surname> <given-names>TJ</given-names></string-name></person-group>, in sod. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood. 1. julij <year>1990</year>.;76(1):117–22.</mixed-citation></ref>
<ref id="b11"><label>11.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Heerema</surname> <given-names>NA</given-names></string-name>, <string-name><surname>Carroll</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Devidas</surname> <given-names>M</given-names></string-name>, <string-name><surname>Loh</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Borowitz</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Gastier-Foster</surname> <given-names>JM</given-names></string-name></person-group>, in sod. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children’s oncology group studies: a report from the children’s oncology group. J Clin Oncol. 20. september <year>2013</year>.;31(27):3397–402.</mixed-citation></ref>
<ref id="b12"><label>12.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Mullighan</surname> <given-names>CG</given-names></string-name>, <string-name><surname>Su</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Radtke</surname> <given-names>I</given-names></string-name>, <string-name><surname>Phillips</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>CB</given-names></string-name></person-group>, in sod. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 29. januar <year>2009</year>.;360(5):470–80.</mixed-citation></ref>
<ref id="b13"><label>13.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Clappier</surname> <given-names>E</given-names></string-name>, <string-name><surname>Auclerc</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Rapion</surname> <given-names>J</given-names></string-name>, <string-name><surname>Bakkus</surname> <given-names>M</given-names></string-name>, <string-name><surname>Caye</surname> <given-names>A</given-names></string-name>, <string-name><surname>Khemiri</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions</article-title>. <source>Leukemia</source>. <year>2014</year> <month>Jan</month>;<volume>28</volume>(<issue>1</issue>):<fpage>70</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/leu.2013.277</pub-id><pub-id pub-id-type="pmid">24064621</pub-id><issn>0887-6924</issn></mixed-citation></ref>
<ref id="b14"><label>14.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Borowitz</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Devidas</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hunger</surname> <given-names>SP</given-names></string-name>, <string-name><surname>Bowman</surname> <given-names>WP</given-names></string-name>, <string-name><surname>Carroll</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Carroll</surname> <given-names>WL</given-names></string-name>, <etal>et al.</etal>; <collab>Children’s Oncology Group</collab></person-group>. <article-title>Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study</article-title>. <source>Blood</source>. <year>2008</year> <month>Jun</month>;<volume>111</volume>(<issue>12</issue>):<fpage>5477</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2008-01-132837</pub-id><pub-id pub-id-type="pmid">18388178</pub-id><issn>0006-4971</issn></mixed-citation></ref>
<ref id="b15"><label>15.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Möricke</surname> <given-names>A</given-names></string-name>, <string-name><surname>Zimmermann</surname> <given-names>M</given-names></string-name>, <string-name><surname>Reiter</surname> <given-names>A</given-names></string-name>, <string-name><surname>Henze</surname> <given-names>G</given-names></string-name>, <string-name><surname>Schrauder</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gadner</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000</article-title>. <source>Leukemia</source>. <year>2010</year> <month>Feb</month>;<volume>24</volume>(<issue>2</issue>):<fpage>265</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1038/leu.2009.257</pub-id><pub-id pub-id-type="pmid">20010625</pub-id><issn>0887-6924</issn></mixed-citation></ref>
<ref id="b16"><label>16.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Pui</surname> <given-names>CH</given-names></string-name>, <string-name><surname>Pei</surname> <given-names>D</given-names></string-name>, <string-name><surname>Sandlund</surname> <given-names>JT</given-names></string-name>, <string-name><surname>Ribeiro</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Rubnitz</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Raimondi</surname> <given-names>SC</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia</article-title>. <source>Leukemia</source>. <year>2010</year> <month>Feb</month>;<volume>24</volume>(<issue>2</issue>):<fpage>371</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1038/leu.2009.252</pub-id><pub-id pub-id-type="pmid">20010620</pub-id><issn>0887-6924</issn></mixed-citation></ref>
<ref id="b17"><label>17.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Silverman</surname> <given-names>LB</given-names></string-name>, <string-name><surname>Stevenson</surname> <given-names>KE</given-names></string-name>, <string-name><surname>O’Brien</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Asselin</surname> <given-names>BL</given-names></string-name>, <string-name><surname>Barr</surname> <given-names>RD</given-names></string-name>, <string-name><surname>Clavell</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000)</article-title>. <source>Leukemia</source>. <year>2010</year> <month>Feb</month>;<volume>24</volume>(<issue>2</issue>):<fpage>320</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1038/leu.2009.253</pub-id><pub-id pub-id-type="pmid">20016537</pub-id><issn>0887-6924</issn></mixed-citation></ref>
<ref id="b18"><label>18.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Hunger</surname> <given-names>SP</given-names></string-name>, <string-name><surname>Loh</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Whitlock</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Winick</surname> <given-names>NJ</given-names></string-name>, <string-name><surname>Carroll</surname> <given-names>WL</given-names></string-name>, <string-name><surname>Devidas</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal>; <collab>COG Acute Lymphoblastic Leukemia Committee</collab></person-group>. <article-title>Children’s Oncology Group’s 2013 blueprint for research: acute lymphoblastic leukemia</article-title>. <source>Pediatr Blood Cancer</source>. <year>2013</year> <month>Jun</month>;<volume>60</volume>(<issue>6</issue>):<fpage>957</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1002/pbc.24420</pub-id><pub-id pub-id-type="pmid">23255467</pub-id><issn>1545-5009</issn></mixed-citation></ref>
<ref id="b19"><label>19.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Schmiegelow</surname> <given-names>K</given-names></string-name>, <string-name><surname>Forestier</surname> <given-names>E</given-names></string-name>, <string-name><surname>Hellebostad</surname> <given-names>M</given-names></string-name>, <string-name><surname>Heyman</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kristinsson</surname> <given-names>J</given-names></string-name>, <string-name><surname>Söderhäll</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal>; <collab>Nordic Society of Paediatric Haematology and Oncology</collab></person-group>. <article-title>Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia</article-title>. <source>Leukemia</source>. <year>2010</year> <month>Feb</month>;<volume>24</volume>(<issue>2</issue>):<fpage>345</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1038/leu.2009.251</pub-id><pub-id pub-id-type="pmid">20010622</pub-id><issn>0887-6924</issn></mixed-citation></ref>
<ref id="b20"><label>20.	</label><mixed-citation publication-type="web-page" specific-use="unparsed">PDQ® Pediatric Treatment Editorial Board. PDQ Childhood Acute Lymphoblastic Leukemia Treatment. Bethesda, MD: National Cancer Institute. Posodobljeno: 30. november <year>2018</year>. Dostopno na: <ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq">https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq</ext-link> [citirano 4. januar 2019].</mixed-citation></ref>
<ref id="b21"><label>21.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Balduzzi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Valsecchi</surname> <given-names>MG</given-names></string-name>, <string-name><surname>Uderzo</surname> <given-names>C</given-names></string-name>, <string-name><surname>De Lorenzo</surname> <given-names>P</given-names></string-name>, <string-name><surname>Klingebiel</surname> <given-names>T</given-names></string-name>, <string-name><surname>Peters</surname> <given-names>C</given-names></string-name></person-group>, in sod. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet. 20. avgust <year>2005</year>.;366(9486):635–42.</mixed-citation></ref>
<ref id="b22"><label>22.	</label><mixed-citation publication-type="web-page" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Kuželički</surname> <given-names>NK</given-names></string-name>, <string-name><surname>Šmid</surname> <given-names>A</given-names></string-name>, <string-name><surname>Raščan</surname> <given-names>IM</given-names></string-name>, <string-name><surname>Jazbec</surname> <given-names>J</given-names></string-name></person-group>. 6-MP based maintenance therapy of childhood ALL in Slovenia: a retrospective study from 1970 to 2004. Slov Med J [Internet]. 7. april <year>2015</year>;84(2). Dostopno na: <ext-link ext-link-type="uri" xlink:href="https://vestnik.szd.si/index.php/ZdravVest/article/view/1016">https://vestnik.szd.si/index.php/ZdravVest/article/view/1016</ext-link></mixed-citation></ref>
<ref id="b23"><label>23.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Crews</surname> <given-names>K</given-names></string-name>, <string-name><surname>Lew</surname> <given-names>G</given-names></string-name>, <string-name><surname>Pei</surname> <given-names>D</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bao</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>J</given-names></string-name></person-group>, in sod. Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. Blood. 15. november <year>2013</year>.;122(21):618–618.</mixed-citation></ref>
<ref id="b24"><label>24.      </label><mixed-citation publication-type="unknown" specific-use="linked"><person-group person-group-type="author"><string-name><surname>Hijiya</surname> <given-names>N</given-names></string-name>, <string-name><surname>Sluis</surname> <given-names>IM</given-names> <surname>van der</surname></string-name></person-group>. <article-title>Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.</article-title> Leuk Lymphoma. 2. april <year>2016</year>.;57(4):748–57. <pub-id pub-id-type="doi">10.3109/10428194.2015.1101098</pub-id></mixed-citation></ref>
<ref id="b25"><label>25.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Inaba</surname> <given-names>H</given-names></string-name>, <string-name><surname>Pui</surname> <given-names>CH</given-names></string-name></person-group>. <article-title>Glucocorticoid use in acute lymphoblastic leukemia: comparison of prednisone and dexamethasone</article-title>. <source>Lancet Oncol</source>. <year>2010</year> <month>Nov</month>;<volume>11</volume>(<issue>11</issue>):<fpage>1096</fpage>–<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(10)70114-5</pub-id><pub-id pub-id-type="pmid">20947430</pub-id><issn>1470-2045</issn></mixed-citation></ref>
<ref id="b26"><label>26.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Schmiegelow</surname> <given-names>K</given-names></string-name></person-group>. <article-title>Advances in individual prediction of methotrexate toxicity: a review</article-title>. <source>Br J Haematol</source>. <year>2009</year> <month>Sep</month>;<volume>146</volume>(<issue>5</issue>):<fpage>489</fpage>–<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2141.2009.07765.x</pub-id><pub-id pub-id-type="pmid">19538530</pub-id><issn>0007-1048</issn></mixed-citation></ref>
<ref id="b27"><label>27.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Schmiegelow</surname> <given-names>K</given-names></string-name>, <string-name><surname>Nielsen</surname> <given-names>SN</given-names></string-name>, <string-name><surname>Frandsen</surname> <given-names>TL</given-names></string-name>, <string-name><surname>Nersting</surname> <given-names>J</given-names></string-name></person-group>. <article-title>Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction</article-title>. <source>J Pediatr Hematol Oncol</source>. <year>2014</year> <month>Oct</month>;<volume>36</volume>(<issue>7</issue>):<fpage>503</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1097/MPH.0000000000000206</pub-id><pub-id pub-id-type="pmid">24936744</pub-id><issn>1077-4114</issn></mixed-citation></ref>
<ref id="b28"><label>28.	</label><mixed-citation publication-type="web-page" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Nachman</surname> <given-names>JB</given-names></string-name></person-group>. Osteonecrosis in childhood ALL [Internet]. Let. 117. <year>2011</year>. 2298–2299 str. Dostopno na: <ext-link ext-link-type="uri" xlink:href="http://www.bloodjournal.org/bloodjournal/117/8/2298.full.pdf">http://www.bloodjournal.org/bloodjournal/117/8/2298.full.pdf</ext-link></mixed-citation></ref>
<ref id="b29"><label>29.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Robison</surname> <given-names>LL</given-names></string-name></person-group>. Late Effects of Acute Lymphoblastic Leukemia Therapy in Patients Diagnosed at 0-20 Years of Age. ASH Educ Program Book. 10. december <year>2011</year>.;2011(1):238–42.</mixed-citation></ref>
<ref id="b30"><label>30.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Lennard</surname> <given-names>L</given-names></string-name></person-group>. <article-title>The clinical pharmacology of 6-mercaptopurine</article-title>. <source>Eur J Clin Pharmacol</source>. <year>1992</year>;<volume>43</volume>(<issue>4</issue>):<fpage>329</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1007/BF02220605</pub-id><pub-id pub-id-type="pmid">1451710</pub-id><issn>0031-6970</issn></mixed-citation></ref>
<ref id="b31"><label>31.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Karran</surname> <given-names>P</given-names></string-name>, <string-name><surname>Attard</surname> <given-names>N</given-names></string-name></person-group>. <article-title>Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer</article-title>. <source>Nat Rev Cancer</source>. <year>2008</year> <month>Jan</month>;<volume>8</volume>(<issue>1</issue>):<fpage>24</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1038/nrc2292</pub-id><pub-id pub-id-type="pmid">18097462</pub-id><issn>1474-175X</issn></mixed-citation></ref>
<ref id="b32"><label>32.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Tiede</surname> <given-names>I</given-names></string-name>, <string-name><surname>Fritz</surname> <given-names>G</given-names></string-name>, <string-name><surname>Strand</surname> <given-names>S</given-names></string-name>, <string-name><surname>Poppe</surname> <given-names>D</given-names></string-name>, <string-name><surname>Dvorsky</surname> <given-names>R</given-names></string-name>, <string-name><surname>Strand</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes</article-title>. <source>J Clin Invest</source>. <year>2003</year> <month>Apr</month>;<volume>111</volume>(<issue>8</issue>):<fpage>1133</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1172/JCI16432</pub-id><pub-id pub-id-type="pmid">12697733</pub-id><issn>0021-9738</issn></mixed-citation></ref>
<ref id="b33"><label>33.	</label><mixed-citation publication-type="web-page" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Dervieux</surname> <given-names>T</given-names></string-name>, <string-name><surname>Brenner</surname> <given-names>TL</given-names></string-name>, <string-name><surname>Hon</surname> <given-names>YY</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Hancock</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Sandlund</surname> <given-names>JT</given-names></string-name></person-group>. in sod. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo [Internet]. Let. 100. <year>2002</year>. 1240–1247 str. Dostopno na: <ext-link ext-link-type="uri" xlink:href="http://www.bloodjournal.org/bloodjournal/100/4/1240.full.pdf">http://www.bloodjournal.org/bloodjournal/100/4/1240.full.pdf</ext-link></mixed-citation></ref>
<ref id="b34"><label>34.      </label><mixed-citation publication-type="unknown" specific-use="linked"><person-group person-group-type="author"><string-name><surname>Panetta</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Evans</surname> <given-names>WE</given-names></string-name>, <string-name><surname>Cheok</surname> <given-names>MH</given-names></string-name></person-group>. <article-title>Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells.</article-title> Br J Cancer. 16. januar <year>2006</year>.;94(1):93–100. <pub-id pub-id-type="doi">10.1038/sj.bjc.6602893</pub-id></mixed-citation></ref>
<ref id="b35"><label>35.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Weinshilboum</surname> <given-names>R</given-names></string-name></person-group>. <article-title>Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase</article-title>. <source>Drug Metab Dispos</source>. <year>2001</year> <month>Apr</month>;<volume>29</volume>(<issue>4 Pt 2</issue>):<fpage>601</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">11259360</pub-id><issn>0090-9556</issn></mixed-citation></ref>
<ref id="b36"><label>36.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Appell</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Berg</surname> <given-names>J</given-names></string-name>, <string-name><surname>Duley</surname> <given-names>J</given-names></string-name>, <string-name><surname>Evans</surname> <given-names>WE</given-names></string-name>, <string-name><surname>Kennedy</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Lennard</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Nomenclature for alleles of the thiopurine methyltransferase gene</article-title>. <source>Pharmacogenet Genomics</source>. <year>2013</year> <month>Apr</month>;<volume>23</volume>(<issue>4</issue>):<fpage>242</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/FPC.0b013e32835f1cc0</pub-id><pub-id pub-id-type="pmid">23407052</pub-id><issn>1744-6872</issn></mixed-citation></ref>
<ref id="b37"><label>37.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Milek</surname> <given-names>M</given-names></string-name>, <string-name><surname>Murn</surname> <given-names>J</given-names></string-name>, <string-name><surname>Jaksic</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Lukac Bajalo</surname> <given-names>J</given-names></string-name>, <string-name><surname>Jazbec</surname> <given-names>J</given-names></string-name>, <string-name><surname>Mlinaric Rascan</surname> <given-names>I</given-names></string-name></person-group>. <article-title>Thiopurine S-methyltransferase pharmacogenetics: genotype to phenotype correlation in the Slovenian population</article-title>. <source>Pharmacology</source>. <year>2006</year>;<volume>77</volume>(<issue>3</issue>):<fpage>105</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1159/000093278</pub-id><pub-id pub-id-type="pmid">16691038</pub-id><issn>0031-7012</issn></mixed-citation></ref>
<ref id="b38"><label>38.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Relling</surname> <given-names>MV</given-names></string-name>, <string-name><surname>Schwab</surname> <given-names>M</given-names></string-name>, <string-name><surname>Whirl-Carrillo</surname> <given-names>M</given-names></string-name>, <string-name><surname>Suarez-Kurtz</surname> <given-names>G</given-names></string-name>, <string-name><surname>Pui</surname> <given-names>CH</given-names></string-name>, <string-name><surname>Stein</surname> <given-names>CM</given-names></string-name></person-group>. <article-title>in sod. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update</article-title>. <source>Clin Pharmacol Ther</source>. <year>2018</year> <month>Nov</month>;<volume>•••</volume>:<fpage>17</fpage>.<issn>0009-9236</issn></mixed-citation></ref>
<ref id="b39"><label>39.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Hindorf</surname> <given-names>U</given-names></string-name>, <string-name><surname>Appell</surname> <given-names>ML</given-names></string-name></person-group>. Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function. J Crohns Colitis. julij <year>2012</year>.;6(6):655–9.</mixed-citation></ref>
<ref id="b40"><label>40.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Ford</surname> <given-names>L</given-names></string-name>, <string-name><surname>Kampanis</surname> <given-names>P</given-names></string-name>, <string-name><surname>Berg</surname> <given-names>J.</given-names></string-name></person-group> Thiopurine S-methyltransferase genotype-phenotype concordance: used as a quality assurance tool to help control the phenotype assay. Ann Clin Biochem. marec <year>2009</year>.;46(Pt 2):152–4.</mixed-citation></ref>
<ref id="b41"><label>41.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Chouchana</surname> <given-names>L</given-names></string-name>, <string-name><surname>Narjoz</surname> <given-names>C</given-names></string-name>, <string-name><surname>Roche</surname> <given-names>D</given-names></string-name>, <string-name><surname>Golmard</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Pineau</surname> <given-names>B</given-names></string-name>, <string-name><surname>Chatellier</surname> <given-names>G</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring</article-title>. <source>Pharmacogenomics</source>. <year>2014</year> <month>Apr</month>;<volume>15</volume>(<issue>6</issue>):<fpage>745</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.2217/pgs.14.32</pub-id><pub-id pub-id-type="pmid">24897283</pub-id><issn>1462-2416</issn></mixed-citation></ref>
<ref id="b42"><label>42.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Karas-Kuzelicki</surname> <given-names>N</given-names></string-name>, <string-name><surname>Smid</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tamm</surname> <given-names>R</given-names></string-name>, <string-name><surname>Metspalu</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mlinaric-Rascan</surname> <given-names>I</given-names></string-name></person-group>. From pharmacogenetics to pharmacometabolomics: SAM modulates TPMT activity. Pharmacogenomics. avgust <year>2014</year>.;15(11):1437–49.</mixed-citation></ref>
<ref id="b43"><label>43.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Milek</surname> <given-names>M</given-names></string-name>, <string-name><surname>Karas Kuzelicki</surname> <given-names>N</given-names></string-name>, <string-name><surname>Smid</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mlinaric-Rascan</surname> <given-names>I.</given-names></string-name></person-group> S-adenosylmethionine regulates thiopurine methyltransferase activity and decreases 6-mercaptopurine cytotoxicity in MOLT lymphoblasts. Biochem Pharmacol. 15. junij <year>2009</year>.;77(12):1845–53.</mixed-citation></ref>
<ref id="b44"><label>44.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Milek</surname> <given-names>M</given-names></string-name>, <string-name><surname>Smid</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tamm</surname> <given-names>R</given-names></string-name>, <string-name><surname>Kuzelicki</surname> <given-names>NK</given-names></string-name>, <string-name><surname>Metspalu</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mlinaric-Rascan</surname> <given-names>I</given-names></string-name></person-group>. Post-translational stabilization of thiopurine S-methyltransferase by S-adenosyl-L-methionine reveals regulation of TPMT*1 and *3C allozymes. Biochem Pharmacol. 1. april <year>2012</year>.;83(7):969–76.</mixed-citation></ref>
<ref id="b45"><label>45.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Karas-Kuzelicki</surname> <given-names>N</given-names></string-name>, <string-name><surname>Jazbec</surname> <given-names>J</given-names></string-name>, <string-name><surname>Milek</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mlinaric-Rascan</surname> <given-names>I</given-names></string-name></person-group>. <article-title>Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients</article-title>. <source>Leukemia</source>. <year>2009</year> <month>May</month>;<volume>23</volume>(<issue>5</issue>):<fpage>971</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1038/leu.2008.317</pub-id><pub-id pub-id-type="pmid">18987660</pub-id><issn>0887-6924</issn></mixed-citation></ref>
<ref id="b46"><label>46.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Dorababu</surname> <given-names>P</given-names></string-name>, <string-name><surname>Naushad</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Linga</surname> <given-names>VG</given-names></string-name>, <string-name><surname>Gundeti</surname> <given-names>S</given-names></string-name>, <string-name><surname>Nagesh</surname> <given-names>N</given-names></string-name>, <string-name><surname>Kutala</surname> <given-names>VK</given-names></string-name></person-group>, in sod. Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL. Pharmacogenomics. julij <year>2012</year>.;13(9):1001–8.</mixed-citation></ref>
<ref id="b47"><label>47.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Smid</surname> <given-names>A</given-names></string-name>, <string-name><surname>Karas-Kuzelicki</surname> <given-names>N</given-names></string-name>, <string-name><surname>Jazbec</surname> <given-names>J</given-names></string-name>, <string-name><surname>Mlinaric-Rascan</surname> <given-names>I.</given-names></string-name></person-group> PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy. Sci Rep. 25. julij <year>2016</year>.;6:30244.</mixed-citation></ref>
<ref id="b48"><label>48.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Rutherford</surname> <given-names>K</given-names></string-name>, <string-name><surname>Daggett</surname> <given-names>V</given-names></string-name></person-group>. <article-title>Polymorphisms and disease: hotspots of inactivation in methyltransferases</article-title>. <source>Trends Biochem Sci</source>. <year>2010</year> <month>Oct</month>;<volume>35</volume>(<issue>10</issue>):<fpage>531</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2010.03.007</pub-id><pub-id pub-id-type="pmid">20382027</pub-id><issn>0968-0004</issn></mixed-citation></ref>
<ref id="b49"><label>49.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Chiengthong</surname> <given-names>K</given-names></string-name>, <string-name><surname>Ittiwut</surname> <given-names>C</given-names></string-name>, <string-name><surname>Muensri</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sophonphan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Sosothikul</surname> <given-names>D</given-names></string-name>, <string-name><surname>Seksan</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>NUDT15 c.415C&gt;T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia</article-title>. <source>Haematologica</source>. <year>2016</year> <month>Jan</month>;<volume>101</volume>(<issue>1</issue>):<fpage>e24</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.3324/haematol.2015.134775</pub-id><pub-id pub-id-type="pmid">26405151</pub-id><issn>0390-6078</issn></mixed-citation></ref>
<ref id="b50"><label>50.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Tanaka</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Kato</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hasegawa</surname> <given-names>D</given-names></string-name>, <string-name><surname>Urayama</surname> <given-names>KY</given-names></string-name>, <string-name><surname>Nakadate</surname> <given-names>H</given-names></string-name>, <string-name><surname>Kondoh</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia</article-title>. <source>Br J Haematol</source>. <year>2015</year> <month>Oct</month>;<volume>171</volume>(<issue>1</issue>):<fpage>109</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1111/bjh.13518</pub-id><pub-id pub-id-type="pmid">26033531</pub-id><issn>0007-1048</issn></mixed-citation></ref>
<ref id="b51"><label>51.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Yang</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Landier</surname> <given-names>W</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>C</given-names></string-name>, <string-name><surname>Hageman</surname> <given-names>L</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>C</given-names></string-name></person-group>, in sod. Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic Leukemia. J Clin Oncol. 10. april <year>2015</year>.;33(11):1235–42.</mixed-citation></ref>
<ref id="b52"><label>52.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Moriyama</surname> <given-names>T</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>Y-L</given-names></string-name>, <string-name><surname>Nishii</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ariffin</surname> <given-names>H</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>C</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>T-N</given-names></string-name></person-group>, in sod. Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. Blood. 7. september <year>2017</year>.;130(10):1209–12.</mixed-citation></ref>
<ref id="b53"><label>53.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Stocco</surname> <given-names>G</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Crews</surname> <given-names>KR</given-names></string-name>, <string-name><surname>Thierfelder</surname> <given-names>WE</given-names></string-name>, <string-name><surname>Decorti</surname> <given-names>G</given-names></string-name>, <string-name><surname>Londero</surname> <given-names>M</given-names></string-name></person-group>, in sod. PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet. 1. november <year>2012</year>.;21(21):4793–804.</mixed-citation></ref>
<ref id="b54"><label>54.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Stocco</surname> <given-names>G</given-names></string-name>, <string-name><surname>Cheok</surname> <given-names>MH</given-names></string-name>, <string-name><surname>Crews</surname> <given-names>KR</given-names></string-name>, <string-name><surname>Dervieux</surname> <given-names>T</given-names></string-name>, <string-name><surname>French</surname> <given-names>D</given-names></string-name>, <string-name><surname>Pei</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia</article-title>. <source>Clin Pharmacol Ther</source>. <year>2009</year> <month>Feb</month>;<volume>85</volume>(<issue>2</issue>):<fpage>164</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1038/clpt.2008.154</pub-id><pub-id pub-id-type="pmid">18685564</pub-id><issn>0009-9236</issn></mixed-citation></ref>
<ref id="b55"><label>55.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Wan Rosalina</surname> <given-names>WR</given-names></string-name>, <string-name><surname>Teh</surname> <given-names>LK</given-names></string-name>, <string-name><surname>Mohamad</surname> <given-names>N</given-names></string-name>, <string-name><surname>Nasir</surname> <given-names>A</given-names></string-name>, <string-name><surname>Yusoff</surname> <given-names>R</given-names></string-name>, <string-name><surname>Baba</surname> <given-names>AA</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Polymorphism of ITPA 94C&gt;A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine</article-title>. <source>J Clin Pharm Ther</source>. <year>2012</year> <month>Apr</month>;<volume>37</volume>(<issue>2</issue>):<fpage>237</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2710.2011.01272.x</pub-id><pub-id pub-id-type="pmid">21545474</pub-id><issn>0269-4727</issn></mixed-citation></ref>
<ref id="b56"><label>56.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Smid</surname> <given-names>A</given-names></string-name>, <string-name><surname>Karas-Kuzelicki</surname> <given-names>N</given-names></string-name>, <string-name><surname>Milek</surname> <given-names>M</given-names></string-name>, <string-name><surname>Jazbec</surname> <given-names>J</given-names></string-name>, <string-name><surname>Mlinaric-Rascan</surname> <given-names>I</given-names></string-name></person-group>. <article-title>Association of ITPA genotype with event-free survival and relapse rates in children with acute lymphoblastic leukemia undergoing maintenance therapy</article-title>. <source>PLoS One</source>. <year>2014</year> <month>Oct</month>;<volume>9</volume>(<issue>10</issue>):<fpage>e109551</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0109551</pub-id><pub-id pub-id-type="pmid">25303517</pub-id><issn>1932-6203</issn></mixed-citation></ref>
<ref id="b57"><label>57.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Huang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Tissing</surname> <given-names>WJ</given-names></string-name>, <string-name><surname>de Jonge</surname> <given-names>R</given-names></string-name>, <string-name><surname>van Zelst</surname> <given-names>BD</given-names></string-name>, <string-name><surname>Pieters</surname> <given-names>R</given-names></string-name></person-group>. <article-title>Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia</article-title>. <source>Leukemia</source>. <year>2008</year> <month>Sep</month>;<volume>22</volume>(<issue>9</issue>):<fpage>1798</fpage>–<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1038/leu.2008.66</pub-id><pub-id pub-id-type="pmid">18368069</pub-id><issn>0887-6924</issn></mixed-citation></ref>
<ref id="b58"><label>58.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Radtke</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zolk</surname> <given-names>O</given-names></string-name>, <string-name><surname>Renner</surname> <given-names>B</given-names></string-name>, <string-name><surname>Paulides</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zimmermann</surname> <given-names>M</given-names></string-name>, <string-name><surname>Moricke</surname> <given-names>A</given-names></string-name></person-group>, in sod. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood. 27. junij <year>2013</year>.;121(26):5145–53.</mixed-citation></ref>
<ref id="b59"><label>59.      </label><mixed-citation publication-type="unknown" specific-use="linked"><person-group person-group-type="author"><string-name><surname>Erculj</surname> <given-names>N</given-names></string-name>, <string-name><surname>Kotnik</surname> <given-names>BF</given-names></string-name>, <string-name><surname>Debeljak</surname> <given-names>M</given-names></string-name>, <string-name><surname>Jazbec</surname> <given-names>J</given-names></string-name>, <string-name><surname>Dolzan</surname> <given-names>V</given-names></string-name></person-group>. <article-title>Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia.</article-title> Leuk Lymphoma. junij <year>2012</year>.;53(6):1096–104. <pub-id pub-id-type="doi">10.3109/10428194.2011.639880</pub-id></mixed-citation></ref>
<ref id="b60"><label>60.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Krajinovic</surname> <given-names>M</given-names></string-name>, <string-name><surname>Costea</surname> <given-names>I</given-names></string-name>, <string-name><surname>Primeau</surname> <given-names>M</given-names></string-name>, <string-name><surname>Dulucq</surname> <given-names>S</given-names></string-name>, <string-name><surname>Moghrabi</surname> <given-names>A</given-names></string-name></person-group>. <article-title>Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis</article-title>. <source>Pharmacogenomics J</source>. <year>2005</year>;<volume>5</volume>(<issue>6</issue>):<fpage>374</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1038/sj.tpj.6500332</pub-id><pub-id pub-id-type="pmid">16130010</pub-id><issn>1470-269X</issn></mixed-citation></ref>
<ref id="b61"><label>61.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Lopez-Lopez</surname> <given-names>E</given-names></string-name>, <string-name><surname>Martin-Guerrero</surname> <given-names>I</given-names></string-name>, <string-name><surname>Ballesteros</surname> <given-names>J</given-names></string-name>, <string-name><surname>Garcia-Orad</surname> <given-names>A</given-names></string-name></person-group>. <article-title>A systematic review and meta-analysis of <italic>MTHFR</italic> polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia</article-title>. <source>Pharmacogenomics J</source>. <year>2013</year> <month>Dec</month>;<volume>13</volume>(<issue>6</issue>):<fpage>498</fpage>–<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1038/tpj.2012.44</pub-id><pub-id pub-id-type="pmid">23089671</pub-id><issn>1470-269X</issn></mixed-citation></ref>
<ref id="b62"><label>62.      </label><mixed-citation publication-type="unknown" specific-use="linked"><person-group person-group-type="author"><string-name><surname>Umerez</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gutierrez-Camino</surname> <given-names>Á</given-names></string-name>, <string-name><surname>Muñoz-Maldonado</surname> <given-names>C</given-names></string-name>, <string-name><surname>Martin-Guerrero</surname> <given-names>I</given-names></string-name>, <string-name><surname>Garcia-Orad</surname> <given-names>A.</given-names></string-name></person-group> <article-title>MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy.</article-title> Pharmacogenomics Pers Med. 27. marec <year>2017</year>.;10:69–78. <pub-id pub-id-type="doi">10.2147/PGPM.S107047</pub-id></mixed-citation></ref>
<ref id="b63"><label>63.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Treviño</surname> <given-names>LR</given-names></string-name>, <string-name><surname>Shimasaki</surname> <given-names>N</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Panetta</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>C</given-names></string-name>, <string-name><surname>Pei</surname> <given-names>D</given-names></string-name></person-group>, in sod. Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects. J Clin Oncol. 10. december <year>2009</year>.;27(35):5972–8.</mixed-citation></ref>
<ref id="b64"><label>64.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Ramsey</surname> <given-names>LB</given-names></string-name>, <string-name><surname>Bruun</surname> <given-names>GH</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Treviño</surname> <given-names>LR</given-names></string-name>, <string-name><surname>Vattathil</surname> <given-names>S</given-names></string-name>, <string-name><surname>Scheet</surname> <given-names>P</given-names></string-name></person-group>, in sod. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 1. januar <year>2012</year>.;22(1):1–8.</mixed-citation></ref>
<ref id="b65"><label>65.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Liu</surname> <given-names>S-G</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>C</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>R-D</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>X-X</given-names></string-name>, <string-name><surname>Cui</surname> <given-names>L</given-names></string-name>, <string-name><surname>Li</surname> <given-names>W-J</given-names></string-name></person-group>, in sod. Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. Oncotarget. 11. maj <year>2017</year>.;8(23):37761–72.</mixed-citation></ref>
<ref id="b66"><label>66.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Zgheib</surname> <given-names>NK</given-names></string-name>, <string-name><surname>Akra-Ismail</surname> <given-names>M</given-names></string-name>, <string-name><surname>Aridi</surname> <given-names>C</given-names></string-name>, <string-name><surname>Mahfouz</surname> <given-names>R</given-names></string-name>, <string-name><surname>Abboud</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Solh</surname> <given-names>H</given-names></string-name></person-group>, in sod. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics. avgust <year>2014</year>.;24(8):387–96.</mixed-citation></ref>
<ref id="b67"><label>67.      </label><mixed-citation publication-type="unknown" specific-use="linked"><person-group person-group-type="author"><string-name><surname>Gervasini</surname> <given-names>G</given-names></string-name>, <string-name><surname>de Murillo</surname> <given-names>SG</given-names></string-name>, <string-name><surname>Jiménez</surname> <given-names>M</given-names></string-name>, <string-name><surname>de la Maya</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Vagace</surname> <given-names>JM</given-names></string-name></person-group>. <article-title>Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.</article-title> Gene. 10. september <year>2017</year>.;628:72–7. <pub-id pub-id-type="doi">10.1016/j.gene.2017.07.025</pub-id></mixed-citation></ref>
<ref id="b68"><label>68.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Simon</surname> <given-names>N</given-names></string-name>, <string-name><surname>Marsot</surname> <given-names>A</given-names></string-name>, <string-name><surname>Villard</surname> <given-names>E</given-names></string-name>, <string-name><surname>Choquet</surname> <given-names>S</given-names></string-name>, <string-name><surname>Khe</surname> <given-names>HX</given-names></string-name>, <string-name><surname>Zahr</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy</article-title>. <source>Pharmacogenomics J</source>. <year>2013</year> <month>Dec</month>;<volume>13</volume>(<issue>6</issue>):<fpage>507</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1038/tpj.2012.37</pub-id><pub-id pub-id-type="pmid">23069858</pub-id><issn>1470-269X</issn></mixed-citation></ref>
<ref id="b69"><label>69.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Ansari</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sauty</surname> <given-names>G</given-names></string-name>, <string-name><surname>Labuda</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gagné</surname> <given-names>V</given-names></string-name>, <string-name><surname>Rousseau</surname> <given-names>J</given-names></string-name>, <string-name><surname>Moghrabi</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia</article-title>. <source>Pharmacogenomics J</source>. <year>2012</year> <month>Oct</month>;<volume>12</volume>(<issue>5</issue>):<fpage>386</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1038/tpj.2011.17</pub-id><pub-id pub-id-type="pmid">21606946</pub-id><issn>1470-269X</issn></mixed-citation></ref>
<ref id="b70"><label>70.      </label><mixed-citation publication-type="unknown" specific-use="linked"><person-group person-group-type="author"><string-name><surname>Campbell</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Bateman</surname> <given-names>E</given-names></string-name>, <string-name><surname>Stephenson</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Bowen</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Keefe</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Peters</surname> <given-names>MDJ</given-names></string-name></person-group>. <article-title>Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.</article-title> Cancer Chemother Pharmacol. 1. julij <year>2016</year>.;78(1):27–39. <pub-id pub-id-type="doi">10.1007/s00280-016-3043-5</pub-id></mixed-citation></ref>
<ref id="b71"><label>71.	</label><mixed-citation publication-type="web-page" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Fernandez</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>C</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Daté</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bashford</surname> <given-names>D</given-names></string-name>, <string-name><surname>Larsen</surname> <given-names>E</given-names></string-name></person-group>. in sod. HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies [Internet]. Let. 124. <year>2014</year>. 1266–1276 str. Dostopno na: <ext-link ext-link-type="uri" xlink:href="http://www.bloodjournal.org/bloodjournal/124/8/1266.full.pdf">http://www.bloodjournal.org/bloodjournal/124/8/1266.full.pdf</ext-link></mixed-citation></ref>
<ref id="b72"><label>72.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Chen</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Pei</surname> <given-names>D</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>C</given-names></string-name>, <string-name><surname>Jeha</surname> <given-names>S</given-names></string-name>, <string-name><surname>Cox</surname> <given-names>NJ</given-names></string-name></person-group>, in sod. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther. avgust <year>2010</year>.;88(2):191–6.</mixed-citation></ref>
<ref id="b73"><label>73.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Relling</surname> <given-names>MV</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Das</surname> <given-names>S</given-names></string-name>, <string-name><surname>Cook</surname> <given-names>EH</given-names></string-name>, <string-name><surname>Rosner</surname> <given-names>GL</given-names></string-name>, <string-name><surname>Neel</surname> <given-names>M</given-names></string-name></person-group>, in sod. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol. 1. oktober <year>2004</year>.;22(19):3930–6.</mixed-citation></ref>
<ref id="b74"><label>74.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>French</surname> <given-names>D</given-names></string-name>, <string-name><surname>Hamilton</surname> <given-names>LH</given-names></string-name>, <string-name><surname>Mattano</surname> <given-names>LA</given-names> <suffix>Jr</suffix></string-name>, <string-name><surname>Sather</surname> <given-names>HN</given-names></string-name>, <string-name><surname>Devidas</surname> <given-names>M</given-names></string-name>, <string-name><surname>Nachman</surname> <given-names>JB</given-names></string-name></person-group>, in sod. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood. 1. maj <year>2008</year>.;111(9):4496–9.</mixed-citation></ref>
<ref id="b75"><label>75.      </label><mixed-citation publication-type="unknown" specific-use="unparsed"><person-group person-group-type="author"><string-name><surname>Kawedia</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Kaste</surname> <given-names>SC</given-names></string-name>, <string-name><surname>Pei</surname> <given-names>D</given-names></string-name>, <string-name><surname>Panetta</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Cai</surname> <given-names>X</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>C</given-names></string-name></person-group>, in sod. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 24. februar <year>2011</year>.;117(8):2340–7; quiz 2556.</mixed-citation></ref>
<ref id="b76"><label>76.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Whirl-Carrillo</surname> <given-names>M</given-names></string-name>, <string-name><surname>McDonagh</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Hebert</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Gong</surname> <given-names>L</given-names></string-name>, <string-name><surname>Sangkuhl</surname> <given-names>K</given-names></string-name>, <string-name><surname>Thorn</surname> <given-names>CF</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Pharmacogenomics knowledge for personalized medicine</article-title>. <source>Clin Pharmacol Ther</source>. <year>2012</year> <month>Oct</month>;<volume>92</volume>(<issue>4</issue>):<fpage>414</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/clpt.2012.96</pub-id><pub-id pub-id-type="pmid">22992668</pub-id><issn>0009-9236</issn></mixed-citation></ref>
<ref id="b77"><label>77.	</label><mixed-citation publication-type="journal" specific-use="restruct"><person-group person-group-type="author"><string-name><surname>Day</surname> <given-names>M</given-names></string-name>, <string-name><surname>Rutkowski</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Feuerstein</surname> <given-names>GZ</given-names></string-name></person-group>. <article-title>Translational medicine—a paradigm shift in modern drug discovery and development: the role of biomarkers</article-title>. <source>Adv Exp Med Biol</source>. <year>2009</year>;<volume>655</volume>:<fpage>1</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4419-1132-2_1</pub-id><pub-id pub-id-type="pmid">20047030</pub-id><issn>0065-2598</issn></mixed-citation></ref>
</ref-list>
</back>
</article>
